

ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Diurnal

DNL 66.25p ▼ -1.0 -1.4%Highly Speculative, Small Cap, **Style Neutral**

Market Cap	£93.0m	Quality	37
Enterprise Value	£72.6m	Value	10
Revenue	£6.38m	Momentum	50
Market Cap Rank	1080th / 1827	StockRank™	20

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum			
Relative Strength (%)			
1m	-11.5%	●	
3m	+6.2%	●	
1yr	+74.4%	●	
Volume Change (%)			
10d v 3m	-45.1%	●	
Price vs... (%)			
52w High	-31.4%	●	
50d MA	-3.46%	●	
200d MA	+11.2%	●	

Growth & Value				vs. industry	vs. market
12m Forecast Rolling					
PE Ratio (f)	n/a				
PEG Ratio (f)	n/a				
EPS Growth (f)	n/a	%			
Dividend Yield (f)	n/a	%			
Valuation (ttm)					
Price to Book Value	4.02				
Price to Tang. Book	4.03				
Price to Free Cashflow	n/a				
Price to Sales	14.6				
EV to EBITDA	n/a				

Margin of Safety (beta)			
Broker Target		47%	
Relative to Sector		100%	

Screens Passed 1 / 1

DNL qualifies for **R&D Breakthroughs** Screen... (in **Quality Investing**).


[View Screen](#) · [View Checklist](#)

Quality				vs. industry	vs. market
Return on Capital	-26.3 %				
Return on Equity	-30.7 %				
Operating Margin	-95.3 %				


Financial Summary											Balance Sheet · Income Statement · Cashflow
Year End 30th Jun		2015	2016	2017	2018	2019	2020	TTM	2021E	2022E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	0.073	1.04	6.31	6.38	3.80	12.3	
Operating Profit	£m	-2.99	-6.99	-12.1	-16.8	-14.5	-5.39	-6.08			
Net Profit	£m	-2.94	-6.57	-9.43	-14.6	-12.3	-4.07	-4.70	-11.8	-13.8	
EPS Reported	p	-5.57	-14.9	-17.9	-26.5	-19.7	-4.27	-3.68			
EPS Normalised	p	-5.57	-13.9	-17.9	-26.5	-19.7	-4.27	-3.68	-8.95	-9.83	
EPS Growth	%										
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%				-22,985	-1,391	-85.4	-95.3			-4,077%
ROA	%		-35.4	-34.5	-62.9	-68.3		-26.2			
ROCE	%	-49.4	-24.0	-58.6	-99.4	-132.5	-29.3	-26.3			-65.5%
ROE	%		-41.1	-43.8	-86.1	-88.3	-27.8	-30.7			-57.4%
Cashflow											
Op. Cashflow ps	p	-5.41	-11.4	-19.8	-23.1	-22.0	-5.04	-3.75			
Capex ps	p	0.009	0.000	0.038	0.062	0.099	0.047	0.11			+37.9%
Free Cashflow ps	p	-5.42	-11.4	-19.9	-23.2	-22.1	-5.09	-3.86			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	6.07	30.1	19.9	17.3	9.15	15.4	20.3			+20.5%
Working Capital	£m	6.03	29.2	20.6	16.8	10.9	16.7	20.7			+22.5%
Net Fixed Assets	£m	0.005	0.003	0.018	0.026	0.033	1.69	2.36			+220.5%
Net Debt	£m	-6.05	-26.9	-16.4	-17.3	-9.15	-15.4	-20.3			
Book Value	£m	6.04	25.9	17.1	16.9	10.9	18.4	23.1			+24.9%
Average Shares	m	52.8	44.2	52.8	55.2	62.5	95.3	107.1			+12.6%
Book Value ps	p	11.4	49.1	32.4	27.2	12.9	15.1	16.7			+5.7%

Health Trend				Piotroski F-Score	6
Bankruptcy Risk				Altman Z1-Score	15.4
Earnings Manipulation Risk					High
Magic Formula Score				2262	16% E+
Other Ratios					
Leverage (ttm)	total	-intang	+pension		
Gross Gearing	%				
Net Gearing	%	-87.9	-88.2	-87.9	
Cash / Assets	%	77.2		77.2	
Liquidity (ttm)					
Curr. Ratio	7.45		Asset Turnover	0.27	
Quick Ratio	6.94		Rec's Turnover	14.5	
Interest Cov.	100.0		Stock Turnover	0.59	
Recent History				vs. industry	vs. market
Latest interim period (ended 31st Dec '20) vs. prior year					
Sales Growth	5.84	%			
EPS Growth	n/a	%			
3yr Compound Annual Growth Rate					
Sales Growth	n/a	%			
EPS Growth	n/a	%			
DPS Growth	n/a	%			

Graphical History Current Fiscal Year 2021



Broker Forecasts				30th Jun 2021			30th Jun 2022		
Price Target: 0.99 (+47.31% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				-11.8m	-8.95	-	-13.8m	-9.83	-
1m Change				-812k	-0.64	-	-1.34m	-0.93	-
3m Change				-179k	-2.18	-	-5.08m	-6.26	-



Profile Summary



Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.

Directors: [Martin Whitaker \(CEO\)](#), [Richard Ross \(CSO\)](#), [Samuel Williams \(CHM\)](#), [Alan Raymond \(NED\)](#), [John Goddard \(NID\)](#), [Michael Withe \(OTH\)](#), [John Porter \(OTH\)](#), [David Eckland \(OTH\)](#), [Daniel Nelson Margetson \(OTH\)](#), [Hiep Huatan \(OTH\)](#), [Richard Bungay \(CFO\)](#) 51,

No. of Employees: 33

No. of Shareholders: n/a



Address Heath Park, CARDIFF, CF14 4UJ, United Kingdom

Web <http://www.diurnal.co.uk/>

Phone +44 29 20682069

Contact ()

Auditors PricewaterhouseCoopers LLP


Last Annual	June 30th, 2020	Sector	Healthcare
Last Interim	December 31st, 2020	Industry	Biotechnology & Medical Research
Incorporated	October 28, 2015	Index	FTSE Aim All Share
Public Since	December 24, 2015	Exchange	London Stock Exchange (AIM)
Shares in Issue	138,337,404	Eligible for	an ISA? ✓ a SIPP? ✓
Free Float	131.9m (95.4%)		

DNL Share Price Quote

DNL Share Price Day's Change
GBP
66.25p
▼ **-1.0 -1.4%**
Traded 3:27pm · Minimum 15 min delayed · NMS: 1.50k

Volume	Bid - Ask	Low - High	Spread
372,995	66.0 - 67.0	67.4 - 67.4	151bps
Avg Vol (3m)	Open - Close	12m Range	Beta
471,994	67.2 - 67.2	55.0 - 89.0	1.69

DNL Share Price Performance



Latest DNL News Announcements (delayed)

[More »](#)

Wed 5:32pm	Diurnal Group PLC - Director Dealings
Wed 3:44pm	Diurnal Group PLC - Director Dealings
Wed 1:58pm	Diurnal Group PLC - Holding(s) in Company
Wed 12:08pm	Diurnal Group PLC IP Group PLC - Holding(s) in Company
Wed 7:43am	BRIEF-Diurnal In Agreement With Citrine Medicine For Efmody

Upcoming DNL Events

Recent ↓

Industry Peer Group	
	4D Pharma Compare vs DNL
	AquaBounty Technol... Compare vs DNL
	Redx Pharma Compare vs DNL
	Synairgen Compare vs DNL
	Bioventix Compare vs DNL
	Open Orphan Compare vs DNL
	Silence Therapeuti... Compare vs DNL
	Ergomed Compare vs DNL
Healthcare Biotechnology & Medical Research	